Note: This is rapid coverage: it is certainly not comprehensive, nor does it draw from the Supplementary Appendix which is now available. COMPASS Pathways’ Phase 2b trial of COMP360 psilocybin therapy for treatment-resistant depression has been published in the New England Journal of Medicine. It becomes the largest published psilocybin trial to date, knocking NYU’s psilocybin for alcohol use…


Previous articleConsidering a Career in Psychedelics? Here’s How to Get Started.
Next articlePsychedelic Research Bulletin: October 2022